Wolfe Research’s new Underperform rating on Avantor (AVTR) has put fresh attention on the stock, as the firm pointed to ongoing growth and margin pressures, as well as market share losses in its VWR distribution business.

Avantor’s recent 1 day share price return declined 1.44%, extending a 7 day share price return decline of 3.43%. However, the 30 day share price return rose 25.59%, while the 1 year total shareholder return declined 27.22%. This indicates short term momentum against a weaker multi year experience.

If Wolfe Research’s cautious view has you reassessing your options, it could be worth scanning other areas of the market, starting with 40 healthcare AI stocks

With Avantor stock trading near analyst targets but at an estimated 34% discount to some intrinsic value models, the key question is whether this weakness is creating a potential entry point or whether the market is already pricing in any future recovery.

Most Popular Narrative: 3.6% Undervalued

Avantor stock closed at $9.57 versus a widely followed fair value narrative of $9.92, which frames the Wolfe Research downgrade against a slightly higher long term assessment.

The global growth in demand for biopharmaceuticals and healthcare solutions is being reinforced by Avantor's major contract wins and extensions with large pharma and biotech consortia. These positions Avantor to capture greater market share as end-market funding and patient procedures return to normalized or higher levels, creating sustained potential for above-market revenue growth.

Curious what underpins that fair value for Avantor stock? The narrative leans on modest top line progress, a swing from losses to profits, and a future earnings multiple that sits below many peers, all run through a 9.38% discount rate. The exact mix of growth, margins, and valuation expectations is where the story gets interesting.

Result: Fair Value of $9.92 (UNDERVALUED)

However, the Avantor story also leans on assumptions that could be tested if competitive pricing pressures deepen or if bioprocessing volumes remain weak for an extended period.

Next Steps

With sentiment around Avantor clearly mixed, it makes sense to move quickly, review the underlying data, and decide where you stand on the balance of concerns and potential upsides, starting with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Avantor?

If Avantor has you rethinking your portfolio, now is the moment to check other opportunities using the Simply Wall Street Screener before the next move passes you by.

• Spot potential value opportunities by scanning 44 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
• Strengthen your income stream by reviewing 9 dividend fortresses that focus on higher yielding companies with consistent payout records.
• Reduce portfolio shocks by focusing on 67 resilient stocks with low risk scores designed to highlight companies with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.